Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 34 for:    does botulinumtoxin make
Previous Study | Return to List | Next Study

Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? (WE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02546999
Recruitment Status : Completed
First Posted : September 11, 2015
Last Update Posted : January 11, 2022
Sponsor:
Collaborators:
Norwegian University of Science and Technology
The Hospital of Vestfold
University Hospital of North Norway
Oslo University Hospital
Haukeland University Hospital
Fondation Lenval
Mazowieckie Centrum Neuropsychiatrii, Warszawa
Information provided by (Responsible Party):
St. Olavs Hospital

Brief Summary:
In Norway, about 60% of all children with cerebral palsy (CP) are being treated with botulinum toxin A (BoNT-A) at 6 years of age, mainly in the legs. Despite this widespread use of the drug, the evidence for a positive effect on walking is insufficient. Moreover, large variation in effect is seen by clinicians. The main objective of the present study is to investigate whether injections with BoNT-A in the calf muscles make walking easier in children with spastic CP within 6 months, reflected by reduced energy cost during walking.

Condition or disease Intervention/treatment Phase
Cerebral Palsy Muscle Spasticity Drug: botox Drug: placebo Phase 4

Detailed Description:

This is an industry independent multicentre clinical trial. The randomization will be done by a computer number random generator and will be carried out and held by the unit of Applied Clinical Research at NTNU. Two strata: age and center.

The study will be conducted according to Consort guidelines and guidelines for Good Clinical Practice. It is approved by the local Ethical committee (REK Nord) and the Norwegian Drug Agency.

Primary research question is: Do BoNT-A injections in the calf muscles make walking easier in children with CP? Secondary research questions: 1) Do BoNT-A injections in the calf muscles increase activity? 2) Do BoNT-A injections in the calf muscles improve walking capacity 3) Do BoNT-A injections in the calf muscles improve perceived performance and satisfaction related to mobility tasks and 4) Do BoNT-A injections in the calf muscles reduce recurrent musculoskeletal pain? The participants will receive the treatment with both local anaesthesia and conscious sedation with oral or nasal benzodiazepines.Outcome measures are made at baseline and 4, 12 and 24 weeks after treatment, with primary endpoint at 12 weeks.

Data will be analyzed using a linear mixed model (LMM). The difference in change in the primary outcome measure (energy cost during walking) between the treated and placebo groups will be done using a post hoc test following the LMM. Secondary, the same model will be used to test for an effect also at 4 and 24 weeks post injection. Age, GMFCS Level, number of prior BoNT-A treatments and study center will be considered as potential covariates.

A substudy will be conducted within the frames of this RCT, aiming to identify characteristics of those who respond to the treatment compared to those who do not respond (outcome measures 6, 7,8 and 9).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
Study Start Date : September 2015
Actual Primary Completion Date : October 15, 2021
Actual Study Completion Date : October 15, 2021


Arm Intervention/treatment
Experimental: botox
Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
Drug: botox
The agent will be given only once at point zero in the time scheme for the project.
Other Name: botulinum toxin A

Placebo Comparator: placebo
Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
Drug: placebo
The agent will be given only once at point zero in the time scheme for the project.
Other Name: sodium chloride




Primary Outcome Measures :
  1. Energy cost during walking [ Time Frame: 6 months ]
    Will be measured by a 5 minutes walk test (overground walking at comfortable speed) with simultaneous gas exchange.


Secondary Outcome Measures :
  1. Activity [ Time Frame: 6 months ]
    Daily activity, measured by a body worn accelerometer over 4 periods of 7 consecutive days.

  2. Perceived improved performance and satisfaction [ Time Frame: 6 months ]
    Assessed by The Canadian Occupational Performance Measure

  3. Recurrent musculoskeletal pain [ Time Frame: 6 months ]
    Assessed by the Child Health Questionnaire (Norwegian version), and elements from the Brief Pain Inventory (Norwegian version)

  4. Walking capacity [ Time Frame: 6 months ]
    Assessed with OMNI-RPE (OMNI Rating of Perceived Exertion) and a 1 Minute walk test at maximal gait speed


Other Outcome Measures:
  1. Gait pattern [ Time Frame: 6 months ]
    3D gait analysis will be carried out on a subset of participants.

  2. Ankle strength [ Time Frame: 6 months ]
    Isometric strength of ankle plantar- and dorsiflexors, will be made on a subset of the participants.

  3. Spasticity [ Time Frame: 6 months ]
    Will be assessed by the use of Tardieu scale. On a subset of participants, concurrent velocity, position and muscle activation will be measured.

  4. Self-perceived effect on walking [ Time Frame: 4 weeks ]
    A qualitative interview will be conducted on a subset of the participants at baseline and post 1 (4 weeks post injection)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Diagnosed with unilateral or bilateral CP
  • GMFCS level I and II
  • Signed informed consent
  • expected cooperation of the patients for the treatment and follow up.

Exclusion Criteria:

  • BoNT-A injections in the lower legs in the last 6 months before intervention
  • history of adverse reactions to BoNT-A
  • Known hypersensitivity to BoNT-A or to any of the excipients
  • Orthopedic surgery in the legs in the last 2 years
  • Major cognitive impairments (must be able to take verbal instructions and conduct the test procedure)
  • infection at the proposed injection site(s)
  • Subclinical or clinical evidence of defective neuromuscular transmission e.g. myasthenia gravis or Lambert-Eaton Syndrome in patients with peripheral motor neuropathic diseases (e.g. amyotrophic lateral sclerosis or motor neuropathy)
  • other underlying neurological disorders that may be affected by BoNT-A injections
  • Use of aminoglycoside antibiotics or spectinomycin, or other medicinal products that interfere with neuromuscular transmission (e.g. neuromuscular blocking agents)
  • Pregnant or breast-feeding
  • Childbearing potential not using contraception
  • any reason why, in the opinion of the investigator, the patient should not participate
  • Children needing deep sedation under treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02546999


Locations
Layout table for location information
France
Lenval Foundation Children's Hospital
Nice, France
Norway
Haukeland University Hospital
Bergen, Norway, 5000
Oslo University Hospital
Oslo, Norway
University Hospital of North-Norway
Tromsø, Norway
Department of Orthopaedic Surgery, St. Olavs University Hospital
Trondheim, Norway
Vestfold Hospital trust
Tønsberg, Norway
Poland
Mazowieckie Centrum Neuropsychiatrii, Zagorze
Warsaw, Poland
Sponsors and Collaborators
St. Olavs Hospital
Norwegian University of Science and Technology
The Hospital of Vestfold
University Hospital of North Norway
Oslo University Hospital
Haukeland University Hospital
Fondation Lenval
Mazowieckie Centrum Neuropsychiatrii, Warszawa
Investigators
Layout table for investigator information
Study Director: Petter Aadahl, md prof St. Olavs Hospital
Publications:
Layout table for additonal information
Responsible Party: St. Olavs Hospital
ClinicalTrials.gov Identifier: NCT02546999    
Other Study ID Numbers: 2013/1195
2014-002539-32 ( EudraCT Number )
First Posted: September 11, 2015    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by St. Olavs Hospital:
Botulinum Toxins, Type A
Walking
Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A
Muscle Spasticity
Cerebral Palsy
Neurologic Manifestations
Nervous System Diseases
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents